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Abstract 
Inflammatory pain is caused by direct stimulation of nociceptors with the 
release of inflammatory mediators. Several studies about the roles of immune 
and opioid systems in the pain process have suggested that their crosstalk may 
have be in pain modulation. Purpose of this study was to review the effect of 
immune and opioid systems on pain modulation. Increasing demand for 
mitigating inflammatory pain has led to the introduction of the effect of 
immune and opioid system interaction in pain modulation. We reviewed 61 
related articles from 1991 to 2016. In this study, we reviewed most of the 
existing papers on the role of opioid system in pain modulation especially with 
a focus of the immune system efficacy. Our review suggested that there is a 
close correlation between the expression of cytokines and opioid receptors. In 
addition, there is relationship in the process of inflammatory pain where 
immune cells have a notable effect on the expression of cytokines and opioid 
receptors. In the process of inflammation, different types of immune cells 
constitute a major source of opioid peptides. The endogenous opioids could 
modulate either their own secretion or secretion of other cytokines. They have 
also anti-nociceptive and anti-inflammatory effects. Exacerbation of immune 
and opioid system reactions via correlation between cytokines and opioid 
peptides in the context of inflammatory pain arises the possibility of the role 
of interaction of these two important systems in the pain process. 
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Introduction 
Pain is described as an unpleasant sensory and 
emotional feeling accompanied by psychological and 
physiological components. The physiology of pain has 
been well described and the underlying origin of all 
type of pain is inflammation and inflammatory 
response (1–3). Inflammation, as a non-specific 
immune response, occurs in reaction to various kinds 
of injuries and can fuel a self-propelling cycle of neural 
death (4). In inflammatory diseases, rapid release of 
inflammatory mediators causes different alterations. 
Inflammatory factors sensitize the specialized sensory 
neurons leading to pain and disability, the principal 
clinical features of inflammation (5). Thus, immune 
system has an important role in the pain process. On 
the other hand, endogenous opioid system is the innate 
pain-relieving systems, which has an essential role in 
pain modulation. There is no clear study about the role 
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of interaction of these two systems in pain control. 
Therefore, in this review, we have highlighted the 
potential role of this interaction in pain modulation. 
In this review, we probed into the effect of 
immune and opioid system interaction in pain 
modulation. The literature covers a variety of topics 
such as inflammation, immune system and pain 
interaction, opioid system and pain, and immune-
opioid system interaction (Figure 1). In this study, we 
reviewed most of the existing papers on immune and 
opioid systems and the possible role of their interaction 
in pain modulation. 
 
Inflammation, interaction between immune system 
and pain  
Immune system sometimes involve in etiology 
and pathophysiology of inflammation. It is also one of 
the main players in the generation of hyperalgesia. 
Immune cells have an important role as pain 
modulators both in peripheral and in central nerve 
damages (5). Various immune cell types have 
contribute in abnormal pain sensitivity via releasing a 
wide range of inflammatory cytokines though to 
varying degrees (6). A large number of evidence 
suggests that cytokines have a crucial role in chronic 
pain and development of hyperalgesia and might alter 
the electrophysiological properties of neurons (7). 
Actions of cytokines include numerous effects on 
immune cells and modulation of inflammatory 
responses. Note that the outcome of cytokines’ action 
greatly depends on where and when they are activated 
exactly. 
It is interesting to note that several cytokines can 
induce their own production as well as the other 
cytokines, such as TNF- which induces production of 
IL-1b and IL-6 (8). IL-10 is another inflammatory 
cytokine, which has been extensively studied. It is 
increasingly stated that IL-10 is one of the most 
important immune-regulating cytokines, which was 
previously called cytokine synthesis inhibiting factor 
(9). In contrast, Conti et al. concluded that this factor 
fails to inhibit the release of IL-6 from human 
umbilical cord mast cells (10). 
IL-6 is known as pro- and anti-inflammatory 
factor during different stages of inflammation. It is 
involved in modulation of the opioid pathway, which 
alters the responses to thermal or mechanical stimuli 
and pain in animals. Previous work in our laboratory 
has emphasized the important time-dependent 
relationship between serum levels of this factor and 
hyperalgesia during adjuvant-induced arthritis (7,11). 
In case of neuro-inflammatory pain, it has been 
suggested that chemokines act as messengers between 
peripheral immune cells and sensory afferent neurons 
at inflamed sites (12). 
Under inflammatory conditions, inflammatory 
factors induce the expression of opioids, while in some 
conditions they might have anti-nociceptive effects. 
 
Figure 1. Flowchart of this study. 
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These factors have important homeostatic functions 
such as repairing tissues. Meanwhile, an imbalance in 
the immune response towards inflammation might 
contribute to persistent pain. Recently, it has been 
claimed that immune cell products might have a crucial 
role not just in inflammatory pain, but also in 
neuropathic pain caused by damage to peripheral 
nerves or to the CNS (13–15). 
 
Opioid system and pain 
Opioid system definition and components: the opioid 
system is a biological communication system which 
acts through a group of endogenous opioid peptides 
and different classes of opioid receptors (16). In 
addition to nociception and analgesia, the opioid 
system plays significant roles in modulating a large 
number of addictive behaviors and cognitive functions, 
and has functional interaction with the endogenous 
cannabinoid (17–20). Further, in a study by 
Zaringhalam et al. demonstrated that the opioid system 
may also be involved in variations of hyperalgesia 
during 21 days of adjuvant-induced arthritis 
inflammation (21). 
Opioid peptides: three families of opioid peptides have 
been well characterized the endorphins, enkephalins 
and dynorphins (22,23). 
 Endorphins: There are four types of endorphins (, 
, , σ) created in the human body (24,25). During 
severe pain, the endorphins cause an analgesic effects 
in human body, while during stress they act differently 
(26). The available evidence suggests that endorphins 
may have a role in preventing obesity and diabetes as 
well as psychiatric diseases (27). 
 Enkephalins: There are two main forms of 
enkephalins, Met-enkephalin and Leu-enkephalins. 
Enkephalins are involved in the mechanisms of 
modulation of the extrapyramidal system, motivational 
processes, regulation of convulsive states, and 
nociception (28–30).  
 Dynorphins: Dynorphin has been found to broadly 
regulate neuronal excitability in the brain and can 
affect learning, cognition and nociception. In addition, 
depending on the site of production, it also can act as a 
modulator of appetite control and body temperature. 
The increased spinal dynorphin levels observed in the 
neuropathic pain models in several studies indicated 
that dynorphin might be involved in chronic pain (31–
34). 
Opioid receptors: opioid receptors are the peripheral 
terminals of sensory neurons consisting of three 
families of receptors: µ, δ and κ. In addition to the well-
documented role of opioid receptors in pain 
modulatory system, they also play a significant role in 
moderation of hyperalgesia in inflamed tissues. The 
evidence has also suggested a close correlation 
between the expression of cytokines and opioid 
receptors in the process of inflammation (35). 
Pain and opioid system relationship: various studies 
have indicated that sustained pain and inflammation 
cause physiological and pharmacological changes in 
the pain modulatory system (36,37). The μ-opioid 
receptor is the most common receptor associated with 
analgesic therapy during persistent pain. Our previous 
studies also indicated that increased level of spinal μ-
opioid receptor expression was involved in 
hyperalgesia reduction during chronic inflammatory 
phase of AA (38,39). 
In addition, there is increasing evidence that 
peripherally restricted κ opioids effectively relieve 
hyperalgesia, pain, and allodynia. Further, κ opioid 
agonists are particularly efficacious for relieving pain 
associated with visceral inflammation and even 
relieving pain induced by the first and second phase of 
formalin, carrageenan, and CFA (34,40). 
In another study, Wilson et al. demonstrated that 
κ opioids reduce inflammation in adjuvant arthritis 
model via directly inhibiting cytokine release from 
immune cells, specifically IL-4 and TNF from 
macrophages (41). Regardless of psychomimetic and 
dysphoric effects of delta receptors, there is strong 
evidence for the role of delta receptors in reducing 
hyperalgesia in inflammatory conditions and 
neuropathic pain (22,42,43). 
 
Immune system and Opioid interaction 
There is no doubt that opioid system plays an 
essential role in the crosstalk between the immune and 
nervous system. Opioids also function as regulators of 
both cellular and humoral immune responses. Cabot et 
al. demonstrated that within peripheral inflammation, 
immune system as a source of opioid peptides plays a 
sophisticated role in pain modulation (44). 
The findings are consistent with studies 
revealing that opioid peptides are found in many 
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leukocyte subpopulations including lymphocytes, 
monocytes, and granulocytes in the peripheral blood. 
In peripheral inflamed tissues, opioid peptides such as 
b-endorphin, met-enkephalin, dynorphin, and 
endomorphins are produced by leukocytes and 
released upon certain types of stimulation such as 
inflammation and inflammatory factors including IL-
1, IL-4, and TNF- (45). 
Kraus et al. primarily showed that pro-
inflammatory cytokine tumor necrosis factor in human 
T lymphocytes and monocytes induced µ-opioid 
receptor gene transcription in the immunocytes (46). 
TNF-induction of µ-opioid receptors could allow a 
feedback regulation in which the endogenous opioids 
could modulate either their own secretion or secretion 
of other cytokines. Accordingly, many investigations 
support this hypothesis that endogenous opioids act in 
an anti-nociceptive as well as an anti-inflammatory 
manner, though further work should be done to better 
understand it (46). Opioid peptides can bind to opioid 
receptors on sensory neurons and can cause analgesic 
effects. Further, in different phases of inflammation, 
various types of immune cells constitute a major 
source of opioid peptides (47–51). There are two 
important points to emphasize here. First, regardless of 
the direct effect of opioids on the immune function, 
they must act via opioid receptors expressed on 
immune cells. Some studies support the view that 
opioid receptors (mostly κ and δ receptors) expressed 
by various immune cells are the same as neuronal-type 
opioid receptors. There is now considerable evidence 
pointing to the existence of novel morphine selective 
opioid receptors on lymphocytes (52).  
Second, opioids can interfere with the immune 
system, modulating innate and acquired immune 
responses and alter resistance to a variety of infectious 
agents. A key issue regarding different opioids is to 
understand that they show different effects on the 
immune system: immunosuppressive, 
immunostimulatory, or dual effect. Meanwhile, the 
nervous system may release opioid peptides, which can 
bind with the immunocyte opioid receptors in order to 
regulate the immune function. Furthermore, 
immunocytes can regulate immune function by 
secreting opioid peptides like b-endorphin and the 
Dynorphin. Investigations have indicated that opioids 
can operate as cytokines which can induce the 
synthesis of opioid receptors in immune cells and the 
 
Figure 2. Hyperalgesia variation due to alteration of microglial morphology after elimination of spinal C fibers. 
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expression of receptors in neuronal cells (37,52,53).  
 
Microglia and molecular aspects of inflammatory 
pain 
Microglia reside within the central nervous 
system and are activated after various insults such as 
nerve injury by displaying morphological changes and 
upregulation of microglial markers. The expression of 
Iba1 is upregulated in activated microglia following 
inflammatory condition, facial nerve axotomy, and 
viral infections. Activated glia releases various 
substances such as pro-inflammatory cytokines and 
other mediators which can enhance pain transmission 
(54–56). In line with previous studies, Gazerani et al. 
revealed that elimination of peripheral peptidergic 
fibers causes significant changes in the expression of 
TRPV3 and Iba1 molecule as well as hyperalgesia and 
allodynia (54)(Figure 2). Microglia are important 
contributors to the development of enhanced pain 
states as well as to the onset and maintenance of 
inflammation. (57–59). The data published in our 
previous study indicated the role of minocycline in 
reducing edema and hyperalgesia during different 
stages of inflammation caused by CFA. The continuing 
injection of minocycline could reduce the 
inflammatory symptoms such Asallodynia, where the 
effect of minocycline on allodynia and spinal Iba1 
expression is age dependent (4,60). Interestingly, in 
another study, Nazemi et al. indicated that anti-
nociceptive effect of morphine decreases during the 
development of neuropathic pain, and use of agents 
selectively inhibiting microglial activity may maintain 
the beneficial effect of opioids in neuropathic pain 
(56). 
Conclusion 
Although some evidence supports the role of 
immune and opioid system in pain control via separate 
mechanisms, various studies indicated the effect of 
crosstalk of these two systems on the process of pain. 
In this regard, as previously mentioned, cytokines 
induce expression of opioid receptors in immunocytes. 
Meanwhile, opioids may operate as cytokines, which 
can induce the synthesis of opioid receptors in immune 
cells too. The expression of receptors in neuronal cells 
and immune cells is involved in anti-nociceptive effect 
of the opioid system. Nevertheless, recent data from 
our laboratory have revealed that opioid system itself 
may be involved in variations in hyperalgesia during 
21 days of adjuvant-induced arthritis inflammation. 
Therefore, many aspects of interactions between 
opioid and immune systems have remained 
ambiguous. 
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